Immatics (NASDAQ:IMTX – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.
Earnings and Valuation
This table compares Immatics and Cardiff Oncology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immatics | $115.50 million | 4.53 | -$104.98 million | ($0.66) | -6.64 |
| Cardiff Oncology | $688,000.00 | 315.13 | -$41.44 million | ($0.94) | -4.51 |
Cardiff Oncology has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Immatics | -47.94% | -15.90% | -9.38% |
| Cardiff Oncology | -6,238.17% | -73.97% | -60.40% |
Volatility and Risk
Immatics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
Insider and Institutional Ownership
64.4% of Immatics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 7.8% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings for Immatics and Cardiff Oncology, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immatics | 0 | 0 | 4 | 1 | 3.20 |
| Cardiff Oncology | 0 | 0 | 3 | 0 | 3.00 |
Immatics presently has a consensus price target of $16.67, indicating a potential upside of 280.52%. Cardiff Oncology has a consensus price target of $11.67, indicating a potential upside of 175.16%. Given Immatics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Immatics is more favorable than Cardiff Oncology.
Summary
Immatics beats Cardiff Oncology on 10 of the 15 factors compared between the two stocks.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
